BMY•benzinga•
The FDA Has Reassigned Prescription Drug User Fee Act Date For Bristol Myers Squibb's Subcutaneous Formulation Of Opdivo (Nivolumab) Across All Previously Approved Adult, Solid Tumor Opdivo Indications. The Updated Goal Date Is December 29
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2024 by benzinga